Previous close | 32.89 |
Open | N/A |
Bid | 0.00 |
Ask | 0.00 |
Strike | 160.00 |
Expiry date | 2024-05-17 |
Day's range | 32.89 - 32.89 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that its Board of Directors has elected Robert (Rob) B. Carter, a seasoned technology executive, to serve as a director. Including Mr. Carter, the company's Board has 10 members.
Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock on July 8, 2024.
A rise in the use of recreational marijuana use in states that have legalized cannabis appears to be behind a spike in falsified workplace drug tests.